Ligand Pro unveils AI model, accelerates drug screening 30-fold
Ligand Pro, a company founded by Skoltech professors and a Ph.D. student, has introduced Matcha, an AI-powered molecular docking model that enhances virtual drug screening speed by 30 times. This development surpasses existing models in accuracy and physical correctness. The innovation opens new avenues for drug development even as traditional methods lag behind.
Matcha Model Capabilities
Matcha, developed by Ligand Pro, enhances the speed of virtual drug screening by a factor of 30 compared to traditional models. The model was created by a team at Skoltech, including professors and a Ph.D. student. It outperforms the AlphaFold class models, which were developed by Nobel laureates, in both accuracy and physical correctness. This advancement is significant for early-stage drug development processes.
Impact on Drug Development
The introduction of Matcha could significantly reduce the time and cost associated with drug candidate screening. Skoltech's involvement highlights the institution's role in cutting-edge research and innovation. The model's enhanced accuracy may lead to more effective drug discovery, potentially benefiting pharmaceutical companies globally. This development comes as the industry seeks faster and more reliable methods for drug development.
What's Next
Ligand Pro plans to integrate Matcha into broader drug development workflows. It remains unclear how quickly pharmaceutical companies will adopt this new technology.
1 source
Ligand Pro unveils AI model, accelerates drug screening 30-fold
